GlobeNewswire: Immucor, Inc. Contains the last 10 of 84 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:57:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/10/04/2527762/0/en/Immucor-and-Pirche-announce-multi-year-partnership.html?f=22&fvtc=4&fvtv=11175Immucor and Pirche announce multi-year partnership2022-10-04T12:04:00Z<![CDATA[NORCROSS, Ga. and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, and Pirche AG, the global leader in AI-powered molecular matching and prediction analysis, announced a multi-year partnership to expand Immucor’s transplant diagnostics software, representing a continued contribution of novel approaches to innovate in the field of histocompatibility. Immucor will also make an investment in Pirche as part of this partnership.]]>https://www.globenewswire.com/news-release/2022/03/04/2397296/0/en/Immucor-Announces-New-Innovations-in-Transplant-Diagnostics.html?f=22&fvtc=4&fvtv=11175Immucor Announces New Innovations in Transplant Diagnostics2022-03-04T18:18:11Z<![CDATA[NORCROSS, Ga., March 04, 2022 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics announced two additions to its transplant diagnostics portfolio, demonstrating their ongoing commitment to new advancements in the field of histocompatibility.]]>https://www.globenewswire.com/news-release/2021/04/26/2217146/0/en/Palmetto-GBA-Finalizes-Local-Coverage-Determination-LCD-for-Liquid-Biopsies-for-Solid-Organ-Transplantation-Including-Immucor-s-kSORT-Assay.html?f=22&fvtc=4&fvtv=11175Palmetto GBA Finalizes Local Coverage Determination (LCD) for Liquid Biopsies for Solid Organ Transplantation, Including Immucor’s kSORT Assay2021-04-26T19:10:00Z<![CDATA[NORCROSS, Ga., April 26, 2021 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, announced that Palmetto MolDX has finalized a local coverage determination (LCD) for Molecular Testing for Solid Organ Allograft Rejection. The policy change, which takes effect June 6, 2021, will enable patients to benefit from Immucor’s kSORT, an innovative, non-invasive gene expression assay designed to better monitor and support the health of solid organ transplant recipients.]]>https://www.globenewswire.com/news-release/2020/07/07/2058951/0/en/Immucor-Announces-Successful-Refinancing.html?f=22&fvtc=4&fvtv=11175Immucor Announces Successful Refinancing2020-07-07T20:39:21Z<![CDATA[Transaction provides company with additional resources and flexibility to advance long-term growth strategy Transaction provides company with additional resources and flexibility to advance long-term growth strategy]]>https://www.globenewswire.com/news-release/2019/04/30/1812910/0/en/Immucor-Announces-Health-Canada-Approval-for-NEO-Iris-Next-Generation-Fully-Automated-Instrument-for-Transfusion-Medicine.html?f=22&fvtc=4&fvtv=11175Immucor Announces Health Canada Approval for NEO Iris™; Next Generation, Fully Automated Instrument for Transfusion Medicine2019-04-30T16:21:39Z<![CDATA[Highest throughput for immunohematology now powered with clearer results for brilliant performance Highest throughput for immunohematology now powered with clearer results for brilliant performance]]>https://www.globenewswire.com/news-release/2019/01/11/1690665/0/en/UPDATE-Immucor-Announces-Health-Canada-Approval-for-Echo-Lumena-Next-Generation-Fully-Automated-Instrument-Powers-Smaller-to-Mid-Volume-Labs.html?f=22&fvtc=4&fvtv=11175UPDATE - Immucor Announces Health Canada Approval for Echo Lumena™; Next Generation, Fully Automated Instrument Powers Smaller to Mid-Volume Labs2019-01-11T22:00:58Z<![CDATA[Faster, clearer blood compatibility results now available Faster, clearer blood compatibility results now available ]]>https://www.globenewswire.com/news-release/2019/01/11/1690625/0/en/Immucor-Announces-Health-Canada-Approval-for-Echo-Echo-Lumena-Next-Generation-Fully-Automated-Instrument-Powers-Smaller-to-Mid-Volume-Labs.html?f=22&fvtc=4&fvtv=11175Immucor Announces Health Canada Approval for Echo Echo Lumena™; Next Generation, Fully Automated Instrument Powers Smaller to Mid-Volume Labs2019-01-11T19:48:03Z<![CDATA[Faster, clearer blood compatibility results now available Faster, clearer blood compatibility results now available ]]>https://www.globenewswire.com/news-release/2018/11/08/1648430/0/en/Immucor-Announces-FDA-Clearance-for-NEO-Iris-Next-Generation-Fully-Automated-Instrument-for-Transfusion-Medicine.html?f=22&fvtc=4&fvtv=11175Immucor Announces FDA Clearance for NEO Iris™; Next Generation, Fully Automated Instrument for Transfusion Medicine2018-11-08T19:46:25Z<![CDATA[Highest throughput for immunohematology now powered with clearer results for brilliant performance NORCROSS, Ga., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that its next generation, fully automated NEO® instrument, NEO Iris™, has received FDA clearance in the United States. NEO Iris, Immucor’s sixth generation immunohematology instrument, underscores Immucor’s unprecedented decades-long commitment to safely and fully automate the blood bank. NEO Iris has the broadest test menu for mid- to high-volume, high-throughput blood testing performed in hospitals, donor centers and clinical reference laboratories.]]>https://www.globenewswire.com/news-release/2018/04/30/1490383/0/en/Immucor-Announces-FDA-Clearance-for-Echo-Lumena-TM-Next-Generation-Fully-Automated-Instrument-Powers-Smaller-to-Mid-Volume-Labs.html?f=22&fvtc=4&fvtv=11175Immucor Announces FDA Clearance for Echo Lumena(TM); Next Generation, Fully Automated Instrument Powers Smaller to Mid-Volume Labs2018-04-30T21:25:09Z<![CDATA[Faster, clearer blood compatibility results now available Faster, clearer blood compatibility results now available]]>https://www.globenewswire.com/news-release/2018/01/16/1289889/0/en/Avi-Pelossof-Appointed-President-and-CEO-of-Immucor.html?f=22&fvtc=4&fvtv=11175Avi Pelossof Appointed President and CEO of Immucor2018-01-16T14:00:00Z<![CDATA[NORCROSS, Ga., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Immucor, Inc., a global leader in transfusion and transplantation diagnostics and a portfolio company of global alternative asset firm TPG, today announced the appointment of Avi Pelossof as President and Chief Executive Officer, effective immediately. Pelossof succeeds CEO Jeffrey R. Binder (“Jeff”), who retains his role as Chairman of the Immucor Board of Directors.]]>